Drugdu.com expert's response:

Ventilators: Core Functions, Clinical Applications, and Technological Advances

I. Core Functions: From Physiological Replacement to Organ Protection

Ventilators achieve three primary functions through mechanical ventilation:

Gas Exchange Replacement

When patients cannot maintain adequate oxygenation (PaO₂ < 60 mmHg) or CO₂ elimination (PaCO₂ > 50 mmHg) due to pulmonary diseases (e.g., pneumonia, ARDS) or neuromuscular dysfunction (e.g., spinal cord injury), ventilators directly facilitate gas exchange between alveoli and capillaries by setting tidal volume, respiratory rate, and fraction of inspired oxygen (FiO₂).
Example: In ARDS patients, alveolar surfactant deficiency causes widespread atelectasis. Ventilators maintain alveolar patency using positive end-expiratory pressure (PEEP), reducing intrapulmonary shunting and improving oxygenation.

Respiratory Muscle Unloading

During acute exacerbations of chronic obstructive pulmonary disease (COPD), airway obstruction and intrinsic PEEP increase respiratory workload by 3–5 times normal. Ventilators assume partial or full respiratory effort via positive-pressure ventilation, alleviating muscle fatigue and preventing respiratory failure progression.
Case Study: A COPD patient using noninvasive ventilation (e.g., BiPAP) showed a reduction in respiratory rate from 30 to 16 breaths/min, with a 60% decrease in accessory muscle (e.g., scalene) contraction intensity.

Lung-Protective Strategies

Low tidal volumes (6 mL/kg predicted body weight) and limited plateau pressures (Pplat ≤ 30 cmH₂O) minimize volutrauma and barotrauma risks.
Example: Severe ARDS patients treated with high-frequency oscillatory ventilation (HFOV) receive high-frequency (3–15 Hz), low-tidal-volume (<1 mL/kg) ventilation to avoid alveolar overdistension while promoting secretion clearance via oscillatory waves.

II. Clinical Applications: From Emergency Rescue to Long-Term Support

Acute Respiratory Failure Management

Type I (Hypoxemic): In severe pneumonia, ventilators correct hypoxemia rapidly using high FiO₂ (up to 100%) and PEEP (8–12 cmH₂O), buying time for antimicrobial therapy.

Type II (Hypercapnic): In COPD exacerbations, ventilators reduce respiratory rate (e.g., from 28 to 12 breaths/min) and increase tidal volume to facilitate CO₂ elimination and prevent respiratory acidosis (pH < 7.25).

Perioperative Care

General Anesthesia: Ventilators maintain ventilation (e.g., volume-controlled mode, 8 mL/kg tidal volume) to prevent intraoperative hypoxemia.

Postoperative Respiratory Depression: After thoracic surgery, ventilators assist deep breathing via pressure support ventilation (PSV) to reduce atelectasis risk.

Critical Care Support

Cardiopulmonary Resuscitation (CPR): Ventilators synchronize with chest compressions (10 breaths/min) to avoid excessive intrathoracic pressure and impaired venous return.

Multiorgan Dysfunction Syndrome (MODS): Ventilators stabilize respiratory function as part of organ support, enabling recovery of other organs (e.g., kidneys, liver).

III. Ventilator Selection Criteria

Invasive Ventilators

Indications: Patients requiring tracheal intubation or tracheostomy (e.g., severe ARDS, post-cardiac arrest).
Advantages: Precise control of ventilation parameters (e.g., pressure, flow, timing) and support for complex modes (e.g., synchronized intermittent mandatory ventilation, SIMV).
Risks: Strict aseptic techniques required; prolonged use increases ventilator-associated pneumonia (VAP) risk.

Noninvasive Ventilators

Indications: Mild-to-moderate respiratory failure (e.g., COPD exacerbation, cardiogenic pulmonary edema).
Advantages: Avoid complications of invasive procedures; patients can eat and speak, improving comfort.
Limitations: Air leaks may compromise ventilation efficacy; facial pressure ulcer risk is higher.

High-Frequency Oscillatory Ventilation (HFOV)

Indications: Severe ARDS patients unresponsive to conventional ventilation (e.g., oxygenation index < 100 mmHg).
Principle: High-frequency (3–15 Hz), low-tidal-volume (<1 mL/kg) ventilation promotes gas exchange via oscillatory waves while minimizing lung injury.
Challenges: Requires close hemodynamic monitoring to avoid circulatory depression from excessive mean airway pressure.

IV. Key Parameter Settings and Adjustment Principles

Initial Settings

Mode Selection: Volume-controlled ventilation (ACV) for patients without spontaneous breathing; SIMV or PSV for those with partial spontaneous effort.

Tidal Volume: 6–8 mL/kg predicted body weight (e.g., 360–480 mL for a 60 kg patient).

Respiratory Rate: 12–20 breaths/min, adjusted based on PaCO₂ targets (e.g., lower rates in COPD to prolong expiratory time).

FiO₂: Start at 100%, then titrate downward to the lowest concentration maintaining SpO₂ ≥ 92% to avoid oxygen toxicity.

Dynamic Adjustments

Arterial Blood Gas (ABG) Monitoring: Recheck ABG every 4–6 hours; adjust parameters based on PaO₂, PaCO₂, and pH.

End-Tidal CO₂ (ETCO₂): Target 35–45 mmHg; persistent elevation may indicate inadequate ventilation or increased intrinsic PEEP.

Plateau Pressure (Pplat): Reflects alveolar pressure; keep ≤ 30 cmH₂O to reduce barotrauma risk.

V. Complication Prevention and Management

Ventilator-Associated Pneumonia (VAP)

Prevention: Elevate head of bed to 30°–45°, assess weaning feasibility daily, perform subglottic suctioning regularly, and use antimicrobial-coated tracheal tubes.
Diagnosis: Fever, leukocytosis, new pulmonary infiltrates, and positive sputum culture after 48 hours of mechanical ventilation.

Barotrauma

Manifestations: Subcutaneous emphysema, pneumomediastinum, pneumothorax.
Prevention: Limit Pplat ≤ 30 cmH₂O; avoid sudden increases in inspiratory pressure or PEEP.

Weaning Failure

Assessment: Rapid Shallow Breathing Index (RSBI) = respiratory rate/tidal volume (L); <105 breaths/min/L predicts high weaning success.
Strategy: Conduct spontaneous breathing trials (SBT) by gradually reducing pressure support (e.g., from 12 to 5 cmH₂O) and observing patient tolerance.

VI. Recent Technological Advances

Intelligent Ventilation Modes

Neurally Adjusted Ventilatory Assist (NAVA): Uses esophageal electrodes to monitor diaphragmatic electrical activity; ventilator delivers proportional pressure support to optimize patient-ventilator synchrony.

Closed-Loop Control Systems: e.g., IntelliVent-ASV, which automatically adjusts ventilation parameters based on ETCO₂ and SpO₂, reducing manual intervention.

Portable and Home Ventilators

Trilogy Series: Supports both noninvasive and invasive modes; suitable for long-term oxygen therapy (LTOT) and transport.

Stellar 150: Integrates a humidifier and battery for mobile use by patients.

Conclusion

Ventilators are critical devices for treating respiratory failure by precisely controlling ventilation parameters to replace gas exchange, unload respiratory muscles, and protect lungs. Their application requires selecting appropriate modes based on patient pathophysiology (e.g., lung compliance, airway resistance) and dynamically adjusting parameters to balance efficacy and safety. Technological advancements toward intelligence, noninvasiveness, and portability continue to improve patient outcomes and quality of life.